Dr. David Ensz, MD
Claim this profileVelocity Clinical Research
Studies Coronavirus
Studies Flu
7 reported clinical trials
12 drugs studied
Affiliated Hospitals
Meridian Clinical Research
Velocity Clinical Research
More about David Ensz, MD
Clinical Trial Related2 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 0 Active Clinical TrialsTreatments David Ensz, MD has experience with
- Dihydroergotamine
- Placebo
- MVA-BN-RSV Vaccine
- ABNCoV2
- Comirnaty
- CVXGA1
Breakdown of trials David Ensz, MD has run
Flu
Respiratory Syncytial Virus
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does David Ensz, MD specialize in?
David Ensz, MD focuses on Coronavirus and Flu. In particular, much of their work with Coronavirus has involved treating patients, or patients who are undergoing treatment.
Is David Ensz, MD currently recruiting for clinical trials?
No, David Ensz, MD is not currently recruiting for any clinical trials. This may change in the future, so check back later.
Are there any treatments that David Ensz, MD has studied deeply?
Yes, David Ensz, MD has studied treatments such as Dihydroergotamine, Placebo, MVA-BN-RSV vaccine.
What is the best way to schedule an appointment with David Ensz, MD?
Apply for one of the trials that David Ensz, MD is conducting.
What is the office address of David Ensz, MD?
The office of David Ensz, MD is located at: Velocity Clinical Research, Sioux City, Iowa 51106 United States. This is the address for their practice at the Velocity Clinical Research.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.